Precision BioSciences, Inc announced a definitive subscription agreement in a non-brokered private placement of 25,000 shares, par value $0.000005 per share at an offering price of $12 per share for a gross proceeds $300,000 on May 8, 2024. The transaction included participation from Michael Amoroso, Alex Kelly, Dario Scimeca and Jeff Smith. Michael Amoroso, President and Chief Executive Officer of the Company and a member of the Company?s board of directors, who agreed to purchase 8,334 Shares for an aggregate amount of $100,008, Alex Kelly, Chief Financial Officer of the Company, who agreed to purchase 8,334 Shares for an aggregate amount of $100,008, Dario Scimeca, General Counsel of the Company, who agreed to purchase 833 Shares for an aggregate amount of $9,996; and Jeff Smith, Chief Research Officer of the Company, who agreed to purchase 833 Shares for an aggregate amount of $9,996.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.4 USD | -3.79% |
|
-15.47% | -14.16% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.16% | 6.51Cr | |
+34.14% | 5.11TCr | |
-6.54% | 3.94TCr | |
+34.92% | 3.85TCr | |
+12.62% | 2.64TCr | |
-12.11% | 2.62TCr | |
-13.43% | 2.1TCr | |
+43.73% | 1.4TCr | |
+31.81% | 1.25TCr | |
-4.54% | 1.16TCr |
- Stock Market
- Equities
- DTIL Stock
- News Precision BioSciences, Inc.
- Precision BioSciences, Inc. announced that it has received $0.3 million in funding